| ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) (NCT00550745) | Merck Sharp & Dohme LLC | 2007-09-01 |
| Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED) (NCT00551330) | Merck Sharp & Dohme LLC | 2007-09-01 |
| Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047) (NCT00749398) | Merck Sharp & Dohme LLC | 2007-09-01 |
| MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) (NCT00482430) | Merck Sharp & Dohme LLC | 2007-09-01 |
| ROTATEQ Reexamination Study (V260-037) (NCT01074242) | Merck Sharp & Dohme LLC | 2007-09-01 |
| 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064) (NCT01028391) | Merck Sharp & Dohme LLC | 2007-09-01 |
| Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) (NCT00725751) | Merck Sharp & Dohme LLC | 2007-09-01 |
| Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) (NCT00535496) | Merck Sharp & Dohme LLC | 2007-09-01 |
| PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) (NCT00536263) | Merck Sharp & Dohme LLC | 2007-09-01 |
| Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) (NCT00526474) | Merck Sharp & Dohme LLC | 2007-09-01 |
| Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED) (NCT00541229) | Merck Sharp & Dohme LLC | 2007-08-24 |
| Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145) (NCT00693472) | Merck Sharp & Dohme LLC | 2007-08-15 |
| A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) (NCT00769132) | Merck Sharp & Dohme LLC | 2007-08-03 |
| Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004) (NCT00822757) | Merck Sharp & Dohme LLC | 2007-08-01 |
| A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED) (NCT00618995) | Merck Sharp & Dohme LLC | 2007-08-01 |
| A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002) (NCT00943371) | Merck Sharp & Dohme LLC | 2007-08-01 |
| A Study of Gastric Delay in Migraine Patients (3207-003) (NCT00548353) | Merck Sharp & Dohme LLC | 2007-08-01 |
| BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006) (NCT00887601) | Merck Sharp & Dohme LLC | 2007-08-01 |
| Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease (NCT00425165) | Merck Sharp & Dohme LLC | 2007-08-01 |
| A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED) (NCT00647114) | Merck Sharp & Dohme LLC | 2007-08-01 |
| A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078) (NCT01021462) | Merck Sharp & Dohme LLC | 2007-08-01 |
| Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) (NCT00687323) | Merck Sharp & Dohme LLC | 2007-07-30 |
| Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) (NCT00550771) | Merck Sharp & Dohme LLC | 2007-07-16 |
| Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061) (NCT00511108) | Merck Sharp & Dohme LLC | 2007-07-11 |
| MK0524B Bioequivalence Study (0524B-070) (NCT00943124) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695) (NCT01081158) | Merck Sharp & Dohme LLC | 2007-07-01 |
| An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006) (NCT00511472) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Bunionectomy Study (0000-063) (NCT00601458) | Merck Sharp & Dohme LLC | 2007-07-01 |
| 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) (NCT00761735) | Merck Sharp & Dohme LLC | 2007-07-01 |
| A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) (NCT00475735) | Merck Sharp & Dohme LLC | 2007-07-01 |
| A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) (NCT00632931) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) (NCT00485758) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED) (NCT00518622) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Dose-Range Finding Study for MK0893 (0893-008) (NCT00479466) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) (NCT00560950) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) (NCT00479388) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5) (NCT00523211) | Merck Sharp & Dohme LLC | 2007-07-01 |
| A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800) (NCT00782951) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807) (NCT00537316) | Merck Sharp & Dohme LLC | 2007-07-01 |
| The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018) (NCT00401310) | Merck Sharp & Dohme LLC | 2007-07-01 |
| Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999) (NCT00705419) | Merck Sharp & Dohme LLC | 2007-07-01 |
| MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED) (NCT00482729) | Merck Sharp & Dohme LLC | 2007-06-19 |
| MK-0524B Lipid Study (MK-0524B-063) (NCT00479882) | Merck Sharp & Dohme LLC | 2007-06-15 |
| A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707) (NCT00506389) | Merck Sharp & Dohme LLC | 2007-06-06 |
| Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) (NCT01181310) | Merck Sharp & Dohme LLC | 2007-06-01 |
| A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) (NCT00539968) | Merck Sharp & Dohme LLC | 2007-06-01 |
| A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) (NCT00491764) | Merck Sharp & Dohme LLC | 2007-06-01 |
| MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) (NCT00496353) | Merck Sharp & Dohme LLC | 2007-06-01 |
| European Safety Registry in Ulcerative Colitis (P04808) (NCT00705484) | Merck Sharp & Dohme LLC | 2007-06-01 |
| A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009) (NCT00684593) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Re-examination Study For Varivax (V210-059 AM2) (NCT01062061) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) (NCT00687219) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED) (NCT00521924) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Safety and Tolerability of MK0773 in Healthy Older Men (0773-004) (NCT01017458) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) (NCT00486720) | Merck Sharp & Dohme LLC | 2007-06-01 |
| ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) (NCT00535730) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) (NCT00479232) | Merck Sharp & Dohme LLC | 2007-06-01 |
| GARDASIL™ Vaccine Impact in Population Study (V501-033) (NCT01077856) | Merck Sharp & Dohme LLC | 2007-05-29 |
| Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) (NCT00545064) | Merck Sharp & Dohme LLC | 2007-05-23 |
| Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED) (NCT00474370) | Merck Sharp & Dohme LLC | 2007-05-15 |
| Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) (NCT00380367) | Merck Sharp & Dohme LLC | 2007-05-03 |
| MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) (NCT00443703) | Merck Sharp & Dohme LLC | 2007-05-01 |
| MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED) (NCT00443729) | Merck Sharp & Dohme LLC | 2007-05-01 |
| Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460) (NCT00202891) | Merck Sharp & Dohme LLC | 2007-05-01 |
| POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) (NCT00423267) | Merck Sharp & Dohme LLC | 2007-05-01 |
| A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) (NCT00473889) | Merck Sharp & Dohme LLC | 2007-05-01 |
| A Study of MK0657 in Parkinson's Disease Patients (0657-006) (NCT00505843) | Merck Sharp & Dohme LLC | 2007-05-01 |
| A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005) (NCT00511667) | Merck Sharp & Dohme LLC | 2007-05-01 |
| Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED) (NCT00684463) | Merck Sharp & Dohme LLC | 2007-04-11 |
| Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) (NCT00725075) | Merck Sharp & Dohme LLC | 2007-04-10 |
| A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED) (NCT00780585) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Effect of MK0524A on Flushing Caused by Niacin (0524A-056) (NCT00533611) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303) (NCT00493805) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078) (NCT00545584) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) (NCT00725010) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Re-examination Study of EMEND (Aprepitant) (MK-0869-184) (NCT01074255) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Effect of MK0524A on Cholesterol Levels (0524A-048) (NCT00536510) | Merck Sharp & Dohme LLC | 2007-04-01 |
| A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED) (NCT00679055) | Merck Sharp & Dohme LLC | 2007-03-31 |
| Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) (NCT00326183) | Merck Sharp & Dohme LLC | 2007-03-26 |
| Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896) (NCT01340573) | Merck Sharp & Dohme LLC | 2007-03-23 |
| MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED) (NCT00449956) | Merck Sharp & Dohme LLC | 2007-03-12 |
| Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049) (NCT00449930) | Merck Sharp & Dohme LLC | 2007-03-01 |
| Developing World Study for RotaTeq™ (V260-015)(COMPLETED) (NCT00362648) | Merck Sharp & Dohme LLC | 2007-03-01 |
| A Study of V950 in People With Alzheimer Disease (V950-001 AM7) (NCT00464334) | Merck Sharp & Dohme LLC | 2007-03-01 |
| Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) (NCT00423449) | Merck Sharp & Dohme LLC | 2007-03-01 |
| Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma (NCT00443924) | Merck Sharp & Dohme LLC | 2007-03-01 |
| Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) (NCT00432237) | Merck Sharp & Dohme LLC | 2007-03-01 |
| Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057) (NCT00565084) | Merck Sharp & Dohme LLC | 2007-03-01 |
| ZOSTAVAX(R) Local Registration Trial (V211-019) (NCT00444860) | Merck Sharp & Dohme LLC | 2007-03-01 |
| Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) (NCT00443209) | Merck Sharp & Dohme LLC | 2007-02-21 |
| Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) (NCT00689390) | Merck Sharp & Dohme LLC | 2007-02-20 |
| High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) (NCT00457418) | Merck Sharp & Dohme LLC | 2007-02-20 |
| Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) (NCT00442936) | Merck Sharp & Dohme LLC | 2007-02-15 |
| Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158) (NCT00832390) | Merck Sharp & Dohme LLC | 2007-02-14 |
| Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059) (NCT00704132) | Merck Sharp & Dohme LLC | 2007-02-14 |
| RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) (NCT00443846) | Merck Sharp & Dohme LLC | 2007-02-13 |
| Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059) (NCT00604968) | Merck Sharp & Dohme LLC | 2007-02-07 |
| Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031) (NCT01078220) | Merck Sharp & Dohme LLC | 2007-02-06 |
| Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189) (NCT00875394) | Merck Sharp & Dohme LLC | 2007-02-01 |
| MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED) (NCT00518739) | Merck Sharp & Dohme LLC | 2007-02-01 |